Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: CCL5

Summary for CCL5

Gene information	Gene symbol	CCL5
	Ensembl ID	ENSG00000274233
	Entrez ID	6352
	Gene name	C-C motif chemokine ligand 5
	Synonyms	D17S136E\|MGC17164\|RANTES\|SCYA5\|SISd\|TCP228
	Gene type	protein_coding
	UniProtAcc	P13501

Top

Dataset with differentially expressed gene: CCL5

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.708416	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.332604	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.290527	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	-0.462531	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.508483	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.975202	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.785206	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	-0.330763	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.545097	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	-0.747863	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	-0.804537	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.529766	2.68e-14
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.445435	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	0.526359	8.67e-09
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	0.410939	1.38e-04
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.594555	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.273255	1.22e-26
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.988258	1.71e-02
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.343986	2.22e-08
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	NK cells	-0.547846	1.35e-02
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD4+ T cells	-0.460836	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	-0.306911	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	-0.346226	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	-0.557144	1.04e-30
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	0.429593	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	0.396728	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD4+ T cells	-0.731913	1.04e-02
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	1.0978	3.23e-30
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	0.353626	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	0.284856	4.28e-02
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD8+ T cells	-0.377076	1.01e-03
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	0.578141	5.81e-19
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	CD8+ T cells	-0.685211	2.90e-18
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	NK cells	-0.617981	1.86e-11
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.687084	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.853454	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	0.409243	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.799014	3.37e-23
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.380025	6.42e-11
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	-0.597437	2.21e-36
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.454066	1.02e-30

Top

Expression of CCL5 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to CCL5

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Gene symbol	Cell type with DEG	Interaction ID	Interacting pair	Gene A	Gene B	Integrin	Interacting cell type1	Interacting cell type2	Dataset	Timepoint	Condition
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	Mono/Macro	GSE111014	post	resistant
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Mono/Macro	GSE111014	pre	resistant
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	Mono/Macro	GSE161801_IMiD	post	resistant
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	cDCs	GSE161801_IMiD	post	resistant
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	Mono/Macro	GSE161801_IMiD	pre	resistant
CCL5	Mono/Macro	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Mono/Macro	GSE161801_PI	post	resistant
CCL5	Mono/Macro	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	Mono/Macro	GSE161801_PI	post	resistant
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Mono/Macro	GSE161801_PI	pre	resistant
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	Mono/Macro	GSE161801_PI	pre	resistant
CCL5	CD4+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD4+ T cells	Malignant cells	GSE162117	post	resistant
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Erythrocytes	GSE162117	post	resistant
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Malignant cells	GSE162117	post	resistant
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Malignant cells	GSE162117	post	sensitive
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Malignant cells	GSE162117	pre	resistant
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	cDCs	GSE162117	pre	resistant
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	pDCs	GSE162117	pre	resistant
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	Malignant cells	GSE162117	pre	resistant
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	cDCs	GSE162117	pre	resistant
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	pDCs	GSE162117	pre	resistant
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Malignant cells	GSE162117	pre	sensitive
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	Malignant cells	GSE162117	pre	sensitive
CCL5	CD8+ T cells	CPI-SS05B7D3407	CCL5_ACKR1	CCL5	ACKR1	False	CD8+ T cells	Erythrocytes	GSE164551	NA	resistant
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Mono/Macro	GSE164551	NA	resistant
CCL5	CD8+ T cells	CPI-SS05B7D3407	CCL5_ACKR1	CCL5	ACKR1	False	CD8+ T cells	Erythrocytes	GSE164551	NA	sensitive
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Mono/Macro	GSE164551	NA	sensitive
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteTissue	post	resistant
CCL5	CD4+ T cells	CPI-SS0EA05941A	CCL5_CCR4	CCL5	CCR4	False	CD8+ T cells	CD4+ T cells	GSE169246_PacAteTissue	pre	resistant
CCL5	CD4+ T cells	CPI-SS0EA05941A	CCL5_CCR4	CCL5	CCR4	False	NK cells	CD4+ T cells	GSE169246_PacAteTissue	pre	resistant
CCL5	Mono/Macro	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteTissue	pre	resistant
CCL5	Mono/Macro	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	Mono/Macro	GSE169246_PacAteTissue	pre	resistant
CCL5	CD8+ T cells	CPI-SS0EA05941A	CCL5_CCR4	CCL5	CCR4	False	CD8+ T cells	CD4+ T cells	GSE169246_PacAteTissue	pre	resistant
CCL5	CD8+ T cells	CPI-SS0B01D306C	CCL5_CCR5	CCL5	CCR5	False	CD8+ T cells	CD8+ T cells	GSE169246_PacAteTissue	pre	resistant
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteTissue	pre	resistant
CCL5	CD8+ T cells	CPI-SS0B01D306C	CCL5_CCR5	CCL5	CCR5	False	NK cells	CD8+ T cells	GSE169246_PacAteTissue	pre	resistant
CCL5	Mono/Macro	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteTissue	pre	sensitive
CCL5	Mono/Macro	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	Mono/Macro	GSE169246_PacAteTissue	pre	sensitive
CCL5	CD8+ T cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteTissue	pre	sensitive
CCL5	NK cells	CPI-SS0EA05941A	CCL5_CCR4	CCL5	CCR4	False	NK cells	CD4+ T cells	GSE169246_PacBlood	pre	resistant
CCL5	NK cells	CPI-SS0B01D306C	CCL5_CCR5	CCL5	CCR5	False	NK cells	CD8+ T cells	GSE169246_PacBlood	pre	resistant
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	Mono/Macro	GSE169246_PacBlood	pre	resistant
CCL5	NK cells	CPI-SS0B01D306C	CCL5_CCR5	CCL5	CCR5	False	NK cells	pDCs	GSE169246_PacBlood	pre	resistant
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	pDCs	GSE169246_PacBlood	pre	resistant
CCL5	CD4+ T cells	CPI-SS0EA05941A	CCL5_CCR4	CCL5	CCR4	False	CD8+ T cells	CD4+ T cells	GSE169246_PacBlood	pre	resistant
CCL5	CD4+ T cells	CPI-SS0EA05941A	CCL5_CCR4	CCL5	CCR4	False	NK cells	CD4+ T cells	GSE169246_PacBlood	pre	resistant
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	Mono/Macro	GSE169246_PacBlood	pre	sensitive
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	cDCs	GSE169246_PacBlood	pre	sensitive
CCL5	NK cells	CPI-SS0A021DB6E	CCL5_CCR1	CCL5	CCR1	False	NK cells	Mono/Macro	GSE169246_PacTissue	post	resistant
CCL5	CD4+ T cells	CPI-SS0EA05941A	CCL5_CCR4	CCL5	CCR4	False	CD8+ T cells	CD4+ T cells	GSE169246_PacTissue	post	sensitive
CCL5	CD4+ T cells	CPI-SS0EA05941A	CCL5_CCR4	CCL5	CCR4	False	NK cells	CD4+ T cells	GSE169246_PacTissue	post	sensitive
CCL5	NK cells	CPI-SS0EA05941A	CCL5_CCR4	CCL5	CCR4	False	NK cells	CD4+ T cells	GSE169246_PacTissue	post	sensitive

Page: 1 2 3

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating CCL5

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
CCL5	hsa-miR-6778-3p	82.6169	NM_002985
CCL5	hsa-miR-4742-5p	82.4674	NM_002985
CCL5	hsa-miR-146b-5p	81.6941	NM_001278736
CCL5	hsa-miR-146a-5p	81.6941	NM_001278736
CCL5	hsa-miR-7153-5p	81.6941	NM_001278736
CCL5	hsa-miR-645	80.1785	NM_001278736

Page: 1

Top

Motifs and transcription factors (TFs) regulating CCL5

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
CCL5	transfac_pro__M05959	ZFP64 (inferredBy_Orthology).
CCL5	transfac_pro__M06468	ZNF808 (directAnnotation).
CCL5	jaspar__MA1994.1	NKX2-1 (inferredBy_Orthology).
CCL5	metacluster_28.1	NKX2-1; NKX2-1; NKX2-1; NKX2-1; NKX2-2; NKX2-3; NKX2-3; NKX2-3; NKX2-3; NKX2-3; NKX2-3; NKX2-3; NKX2-4; NKX2-4; NKX2-4; NKX2-5; NKX2-5; NKX2-5; NKX2-5; NKX2-6; NKX2-8; NKX2-8; NKX2-8; NKX2-8 (directAnnotation). NKX2-6; NKX2-6; NKX2-6 (inferredBy_Orthology).
CCL5	tfdimers__MD00288	HMGA1; HMGA2; SRY (directAnnotation).
CCL5	transfac_pro__M05723	ZNF19 (directAnnotation).
CCL5	transfac_pro__M06080	ZNF99 (directAnnotation).
CCL5	transfac_pro__M06137	ZNF250 (directAnnotation).
CCL5	dbtfbs__ZNF26_HEK293_ENCSR028EGI_merged_N1	ZNF26 (directAnnotation).
CCL5	transfac_pro__M02095	FOSL1 (directAnnotation).
CCL5	kznf__ZNF614_Imbeault2017_OM_MEME	ZNF614 (directAnnotation).
CCL5	metacluster_172.19	HMGA2 (directAnnotation).
CCL5	metacluster_22.36	BACH2 (directAnnotation).
CCL5	transfac_pro__M04856	BATF (directAnnotation).
CCL5	taipale_tf_pairs__ETV2_DRGX_RSCGGAWRYATTA_CAP_repr	DRGX; ETV2 (directAnnotation).
CCL5	kznf__ZFP82_Schmitges2016_RCADE	ZFP82 (directAnnotation).
CCL5	kznf__ZNF354B_Imbeault2017_RP_RCADE	ZNF354B (directAnnotation).
CCL5	tfdimers__MD00272	ISL1; POU3F1 (directAnnotation).
CCL5	tfdimers__MD00346	DBP; GSX2 (directAnnotation).
CCL5	transfac_pro__M05299	NKX2-6 (directAnnotation).
CCL5	metacluster_22.34	BACH2 (directAnnotation).
CCL5	transfac_pro__M01111	RBPJ (directAnnotation).
CCL5	transfac_pro__M05683	ZNF280A (directAnnotation).
CCL5	taipale_tf_pairs__GCM2_TBX21_NNNCGGGNNNGGTGTNN_CAP_repr	GCM2; TBX21 (directAnnotation).
CCL5	taipale_tf_pairs__TEAD4_ETV1_RSCGGAAATRCM_CAP	ETV1; TEAD4 (directAnnotation).
CCL5	tfdimers__MD00218	ATF1; ATF2; ATF3; ATF4; ATF7; CREB1; CREM; ELF1 (directAnnotation).
CCL5	metacluster_172.6	CHD2; E2F1 (directAnnotation).
CCL5	taipale_tf_pairs__GCM2_PITX1_RTRCGGGSGATTAN_CAP_repr	GCM2; PITX1 (directAnnotation).
CCL5	homer__GGAAATTCCC_NFkB-p65-Rel	RELA (inferredBy_Orthology).
CCL5	transfac_pro__M06552	ZNF420 (directAnnotation).
CCL5	metacluster_22.11	NFE2 (directAnnotation).
CCL5	metacluster_22.18	BACH2 (inferredBy_Orthology).
CCL5	metacluster_2.7	IRF1; IRF1; IRF2; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF7; IRF8; IRF8; IRF9; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; STAT1; STAT1; STAT2 (directAnnotation). PRDM1; PRDM1; PRDM1 (inferredBy_Orthology).
CCL5	metacluster_22.16	BACH2 (directAnnotation).
CCL5	transfac_pro__M06162	ZNF93 (directAnnotation).
CCL5	metacluster_22.13	MAFK (inferredBy_Orthology).
CCL5	transfac_pro__M01239	RELA (directAnnotation).
CCL5	metacluster_2.6	IRF1; IRF1; IRF1; IRF1; IRF1; IRF1; IRF1; IRF1; IRF1; IRF1; IRF2; IRF2; IRF2; IRF2; IRF2; IRF2; IRF2; IRF3; IRF3; IRF3; IRF3; IRF3; IRF3; IRF4; IRF4; IRF4; IRF4; IRF4; IRF5; IRF5; IRF5; IRF5; IRF5; IRF5; IRF5; IRF6; IRF7; IRF7; IRF7; IRF7; IRF7; IRF7; IRF7; IRF8; IRF8; IRF8; IRF8; IRF8; IRF8; IRF8; IRF8; IRF9; IRF9; IRF9; IRF9; IRF9; IRF9; IRF9; STAT1; STAT2; STAT2; STAT2; STAT2; ZNF426; ZNF71 (directAnnotation). IRF1; IRF1; IRF3; IRF8 (inferredBy_Orthology).
CCL5	tfdimers__MD00409	ETS1; YY2 (directAnnotation).
CCL5	transfac_pro__M06807	SALL2 (inferredBy_Orthology).
CCL5	transfac_pro__M06845	ZBTB38 (directAnnotation).
CCL5	taipale_tf_pairs__ETV2_SOX15_RSCGGAANNNNNNYWTTGT_CAP_repr	ETV2; SOX15 (directAnnotation).
CCL5	metacluster_168.11	ZNF771; ZNF771 (directAnnotation).
CCL5	taipale_cyt_meth__ZBTB2_NTTTCCGGTAMN_eDBD_meth_repr	ZBTB2 (directAnnotation).
CCL5	metacluster_168.19	ZNF316 (directAnnotation).
CCL5	transfac_pro__M05805	ZNF546 (directAnnotation).
CCL5	transfac_pro__M05585	HIC2 (directAnnotation).
CCL5	transfac_pro__M06173	ZNF85 (directAnnotation).
CCL5	transfac_pro__M06519	ZNF397 (directAnnotation).
CCL5	kznf__ZNF3_Imbeault2017_RP_RCADE	ZNF3 (directAnnotation).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
CCL5	"Heparin Disaccharide I-S"	DB02322	small molecule
CCL5	"Heparin Disaccharide Iii-S"	DB02353	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."